Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q9H7C9
UPID:
AAMDC_HUMAN
Alternative names:
Adipogenesis associated Mth938 domain-containing protein
Alternative UPACC:
Q9H7C9; Q96AQ4; Q9Y6B1
Background:
The Mth938 domain-containing protein, also known as Adipogenesis associated Mth938 domain-containing protein, is implicated in the early stages of fat cell development. Its role in preadipocyte differentiation and adipogenesis highlights its importance in the complex process of fat tissue formation.
Therapeutic significance:
Understanding the role of Mth938 domain-containing protein could open doors to potential therapeutic strategies. Its involvement in adipogenesis suggests a pivotal function in metabolic diseases, offering a promising target for interventions aimed at obesity and related conditions.